Aytu BioPharma, Inc. (AYTU)

Aytu BioPharma Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Equivalents	26.72	30.95	20.01	22.99	19.36	49.65
Cash & Short-Term Investments	26.72	30.95	20.01	22.99	19.36	49.65
Cash Growth	47.00%	54.71%	-12.96%	18.72%	-61.01%	3.26%
Receivables	24.49	31.16	23.53	28.73	21.71	28.18
Inventory	7.46	11.43	12.14	8.51	10.85	16.34
Prepaid Expenses	8.66	5.64	5.1	5.43	7.38	9.78
Restricted Cash	-	-	-	-	-	0.25
Other Current Assets	-	-	1.12	5.43	0.63	1.04
Total Current Assets	67.33	79.18	61.89	71.08	59.93	105.23
Property, Plant & Equipment	1.32	1.59	1.52	3.61	6.3	8.7
Goodwill	-	-	-	-	-	65.8
Other Intangible Assets	42.49	42.2	52.45	57.44	70.63	85.46
Long-Term Deferred Tax Assets	-	0.25	0.76	1.38	-	-
Other Long-Term Assets	0.56	0.95	1.47	2.96	0.77	0.47
Total Assets	111.69	124.18	118.1	136.46	137.62	265.67

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Accounts Payable	13.21	10.6	10.31	12.55	10.99	19.26
Accrued Expenses	13.43	15.26	22.26	24.54	25.71	30.72
Short-Term Debt	10.41	9.06	2.4	1.56	3.81	7.93
Current Portion of Long-Term Debt	1.86	1.86	1.86	-	-	16.57
Current Portion of Leases	0.2	0.14	0.71	1.34	0.1	0.1
Other Current Liabilities	20.86	26.15	24.69	29.02	23.84	34.86
Total Current Liabilities	59.97	63.06	62.23	69.02	64.44	109.44
Long-Term Debt	9.55	10.9	10.88	14.71	14.2	-
Long-Term Leases	0.92	0.99	0.58	0.83	0.08	0.18
Long-Term Deferred Tax Liabilities	-	0.25	0.76	1.38	-	-
Other Long-Term Liabilities	6.11	30.02	15.94	11.17	14.59	18.48
Total Liabilities	76.55	105.21	90.38	97.11	93.32	128.1

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Common Stock	0	0	0	0	-	0
Additional Paid-In Capital	382.91	352.5	347.69	343.49	331.39	315.86
Retained Earnings	-347.77	-333.54	-319.97	-304.13	-287.08	-178.3
Total Common Equity	35.14	18.97	27.72	39.36	44.31	137.57
Shareholders' Equity	35.14	18.97	27.72	39.36	44.31	137.57
Total Liabilities & Equity	111.69	124.18	118.1	136.46	137.62	265.67

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Total Debt	22.94	22.94	16.42	18.45	18.19	24.78
Net Cash (Debt)	3.78	8.02	3.59	4.53	1.17	24.87
Net Cash Growth	-	123.38%	-20.87%	286.86%	-95.29%	-46.03%
Net Cash Per Share	0.41	1.28	0.65	1.36	0.80	29.70
Filing Date Shares Outstanding	10.73	9.91	6.17	5.53	3.12	1.38
Total Common Shares Outstanding	10.73	8.98	5.97	5.52	1.93	1.37
Working Capital	7.35	16.12	-0.34	2.06	-4.51	-4.2
Book Value Per Share	3.27	2.11	4.64	7.13	22.97	100.08
Tangible Book Value	-7.35	-23.24	-24.74	-18.08	-26.32	-13.7
Tangible Book Value Per Share	-0.68	-2.59	-4.14	-3.28	-13.65	-9.97
Machinery	1.05	1.08	2.78	4.29	4.45	5
Construction In Progress	-	-	-	0.11	-	0.2
Leasehold Improvements	0.16	0.16	0.04	1	1	0.96

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Feb 3, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 30, 2026

Data Sources Report a data error